Delcath Systems, INC 8-K filings

Delcath Systems, Inc. has updated its bylaws to designate exclusive forums for corporate and federal securities claims.

Delcath Systems reported Q2 2026 results, showing revenue growth and raising full-year revenue guidance, though adjusted EBITDA and operating cash flow saw a year-over-year decrease.

Delcath Systems, Inc. announced that its stockholders approved an amendment to its 2020 Omnibus Equity Incentive Plan to increase available shares and ratified the appointment of CBIZ CPAs P.C. as its independent auditor.

Delcath Systems announced first quarter 2026 financial results, with total revenue reaching $25.0 million, and provided full-year revenue guidance of at least $100 million.

Delcath Systems announced the publication of positive CHOPIN clinical trial results in The Lancet Oncology, highlighting the promise of combining percutaneous hepatic perfusion with immunotherapy for metastatic uveal melanoma.

Delcath Systems announced strong financial results for Q4 and full year 2025, with significant revenue growth and positive adjusted EBITDA, alongside an optimistic 2026 outlook.

Delcath Systems announced robust preliminary Q4 and full-year 2025 financial results, including positive operating cash flow and significant revenue growth for its HEPZATO KIT.

Delcath Systems, Inc. announced its board of directors authorized a share repurchase program of up to $25 million of its common stock.

Delcath Systems announced robust third-quarter 2025 financial results, driven by significant HEPZATO KIT revenue growth and positive clinical trial advancements.

Delcath Systems announced preliminary Q3 2025 financial results and positive Phase 2 CHOPIN trial outcomes for metastatic uveal melanoma.

Delcath Systems, Inc. has amended and restated its bylaws to enhance corporate governance, clarify stockholder rights, and update officer duties and indemnification provisions.

Delcath Systems announced robust second-quarter 2025 financial results, driven by significant revenue growth from its HEPZATO KIT and a shift to net income and positive adjusted EBITDA.

Delcath Systems projects significant revenue growth for 2025 and plans to expand patient access through a National Medicaid Drug Rebate Agreement.

Delcath Systems' stockholders approved amendments to the 2020 Omnibus Equity Incentive Plan and the 2021 Employee Stock Purchase Plan at the annual meeting on May 15, 2025.

Delcath Systems announces a profitable first quarter in 2025, driven by significant revenue growth from HEPZATO KIT sales and expansion of treatment centers.

Delcath Systems, Inc. reports that Marcum LLP has resigned as their independent registered accounting firm, and CBIZ CPAs has been engaged as the new firm, effective immediately.

Delcath Systems reports strong financial results for Q4 and full year 2024, driven by the successful launch and adoption of HEPZATO KIT, with positive adjusted EBITDA in the fourth quarter.

Delcath Systems reported robust preliminary financial results for 2024, highlighted by significant revenue growth and a strong cash position, while also outlining plans for future expansion.

Delcath Systems has announced the successful exercise of warrants, resulting in $16.3 million in gross proceeds, which will support the company's commercialization and clinical development plans.

Delcath Systems announced a 44% increase in revenue for the third quarter of 2024, driven by strong sales of HEPZATO KIT, and the elimination of all outstanding debt.

Delcath Systems reports preliminary Q3 2024 revenue of $11.2 million, including $10 million from U.S. sales of HEPZATO KIT, triggering a $25 million warrant exercise.

An independent study shows that liver-directed therapies, including Delcath's CHEMOSAT system, significantly improve survival rates for uveal melanoma patients with liver metastases compared to systemic therapies.

Delcath Systems reports promising outcomes from two independent studies highlighting the efficacy of their CHEMOSAT and HEPZATO KIT systems in treating liver tumors and uveal melanoma.

Delcath Systems reported a significant increase in revenue for the second quarter of 2024, driven by sales of its HEPZATO KIT and CHEMOSAT products.

Delcath Systems has formalized new employment agreements with its CEO, Senior VP of Finance, and General Manager of Interventional Oncology, outlining compensation, benefits, and severance terms.

Delcath Systems has regained compliance with Nasdaq listing rules regarding audit committee composition after appointing a new independent director.

Delcath Systems appointed a new director, Bridget Martell, and is working to regain compliance with Nasdaq listing rules regarding audit committee composition.

Delcath Systems reported a significant increase in revenue and progress in expanding treatment centers for its HEPZATO KIT in the first quarter of 2024.

Delcath Systems has extended its supply agreement with Synerx Pharma for melphalan hydrochloride through December 31, 2028, with new terms for pricing and ordering.

Delcath Systems announced positive fourth quarter and full year 2023 results, highlighted by the successful commercial launch of HEPZATO KIT and an increase in 2024 treatment site activation guidance.